SCHEMBL308676

SCHEMBL308676

O=C(O)c1c[c]ncc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261813 0.80
SCHEMBL8786624 0.79 KMT2A (0.59)
SCHEMBL5592700 0.77 HDAC6 (0.44)
SCHEMBL1031249 0.75 ALDH1A1 (0.46)
SCHEMBL8507209 0.75 ALDH1A1 (0.41)
Isonicotinic Acid SCHEMBL1414914 0.67 NAPRT (1.00)
Isonicotinic Acid SCHEMBL1108 0.67
Isonicotinic Acid SCHEMBL25269381 0.65 NAPRT (0.94)
Isonicotinic Acid SCHEMBL25270920 0.65 NAPRT (0.94)
Isonicotinic Acid SCHEMBL25273146 0.65 NAPRT (0.94)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278996-A1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE S.A. (PL) 2023-09-07 US claimed
CN-108884029-B LSD1 inhibitors 米拉蒂医疗股份有限公司 2021-10-26 CN claimed
CN-110746479-B Compound and preparation method and application thereof 山东师范大学 2021-01-08 CN claimed
EP-3397616-B1 LSD1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2020-06-10 EP claimed
CN-110746479-A Compound and preparation method and application thereof 山东师范大学 2020-02-04 CN claimed
US-10233152-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2019-03-19 US claimed
EP-3397616-A1 LSD1 INHIBITORS Mirati Therapeutics, Inc. (US) 2018-11-07 EP claimed
US-20180127369-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. 2018-05-10 US claimed
US-9809541-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2017-11-07 US claimed
WO-2017116558-A1 LSD1 INHIBITORS Mirati Therapeutics, Inc. (US) 2017-07-06 WO claimed
US-20030199565-A1 Gastrin and cholecystokinin receptor ligands(II) JAMES BLACK FOUNDATION LIMITED (GB) 2003-10-23 US claimed
US-20030069291-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors PFIZER INC. 2003-04-10 US claimed
WO-2002079200-A1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2002-10-10 WO claimed
WO-2001085723-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) JAMES BLACK FOUNDATION LIMITED (GB) 2001-11-15 WO claimed
US-6245988-B1 USEFUL IN A PHOTOVOLTAIC CELL COMPRISING A NANOCRYSTALLINE TITANIUM DIOXIDE LAYER; IMPROVING THE EFFICIENCY OF SOLAR TO ELECTRIC POWER CONVERSION BY PROVIDING PHOTOSENSITIZER HAVING ENHANCED SPECTRAL RESPONSE IN RED/INFRARED REGIONS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2001-06-12 US claimed
EP-0983282-A1 METAL COMPLEX PHOTOSENSITIZER AND PHOTOVOLTAIC CELL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2000-03-08 EP claimed
WO-1998050393-A1 METAL COMPLEX PHOTOSENSITIZER AND PHOTOVOLTAIC CELL ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 1998-11-12 WO claimed
US-5811081-A Use of hydroxybenzotriazoles for enhancing the sun protection factor of cellulosic fibre materials CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-09-22 US claimed
EP-0708197-A2 Utilisation of hydroxybenztriazoles for increasing the sun-ray filter index of fibrous cellulosic materials CIBA-GEIGY AG (CH) 1996-04-24 EP claimed
US-5466571-A Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1995-11-14 US claimed